Federated Hermes Inc. Has $5.46 Million Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Federated Hermes Inc. decreased its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 38.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,814 shares of the company’s stock after selling 11,261 shares during the period. Federated Hermes Inc.’s holdings in Medpace were worth $5,461,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the company. Miller Howard Investments Inc. NY lifted its holdings in Medpace by 1.3% during the 4th quarter. Miller Howard Investments Inc. NY now owns 3,075 shares of the company’s stock valued at $943,000 after purchasing an additional 39 shares during the last quarter. Schulhoff & Co. Inc. raised its stake in shares of Medpace by 2.0% in the third quarter. Schulhoff & Co. Inc. now owns 2,250 shares of the company’s stock valued at $545,000 after acquiring an additional 45 shares during the last quarter. Campbell Newman Asset Management Inc. grew its position in Medpace by 0.4% during the 4th quarter. Campbell Newman Asset Management Inc. now owns 11,095 shares of the company’s stock worth $3,401,000 after acquiring an additional 46 shares during the last quarter. Treasurer of the State of North Carolina increased its holdings in Medpace by 0.5% during the 3rd quarter. Treasurer of the State of North Carolina now owns 10,230 shares of the company’s stock valued at $2,477,000 after purchasing an additional 50 shares in the last quarter. Finally, Sectoral Asset Management Inc. raised its position in Medpace by 4.9% in the 3rd quarter. Sectoral Asset Management Inc. now owns 1,181 shares of the company’s stock valued at $286,000 after purchasing an additional 55 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Analysts Set New Price Targets

MEDP has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft started coverage on Medpace in a research note on Monday, March 18th. They issued a “hold” rating and a $395.00 target price for the company. Guggenheim boosted their target price on shares of Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a research note on Wednesday. StockNews.com raised shares of Medpace from a “hold” rating to a “buy” rating in a research note on Tuesday. UBS Group upgraded shares of Medpace from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $282.00 to $452.00 in a research report on Thursday, February 15th. Finally, Robert W. Baird increased their price objective on Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a research report on Wednesday. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $443.00.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $389.77 on Friday. The stock has a market cap of $12.08 billion, a price-to-earnings ratio of 39.73, a P/E/G ratio of 1.98 and a beta of 1.38. The company has a 50 day moving average of $397.75 and a 200-day moving average of $324.12. Medpace Holdings, Inc. has a one year low of $189.30 and a one year high of $421.00.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, April 22nd. The company reported $3.20 EPS for the quarter, topping analysts’ consensus estimates of $2.45 by $0.75. The firm had revenue of $511.00 million during the quarter, compared to analyst estimates of $512.39 million. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The business’s quarterly revenue was up 17.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.27 EPS. Equities research analysts anticipate that Medpace Holdings, Inc. will post 11.23 earnings per share for the current year.

Insider Buying and Selling

In other Medpace news, VP Susan E. Burwig sold 102 shares of the stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $403.00, for a total value of $41,106.00. Following the transaction, the vice president now owns 15,181 shares of the company’s stock, valued at $6,117,943. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Ashley M. Keating sold 250 shares of the company’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $409.87, for a total value of $102,467.50. Following the completion of the sale, the director now owns 250 shares in the company, valued at approximately $102,467.50. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Susan E. Burwig sold 102 shares of Medpace stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $403.00, for a total value of $41,106.00. Following the transaction, the vice president now owns 15,181 shares in the company, valued at $6,117,943. The disclosure for this sale can be found here. Insiders sold a total of 189,340 shares of company stock valued at $76,651,647 over the last three months. Company insiders own 20.30% of the company’s stock.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.